Biogena’s €475 Million Valuation Casts a Long Shadow Over Subsidiary’s €18.75 Million Market Cap
Published on 07/21/2026 at 18:54 | Redaktion boerse-global.de
The arithmetic is almost too stark to ignore. Biogena Group Invest, the listed subsidiary of the Austrian nutritional-supplement group, carries a market capitalisation of just €18.75 million, yet the parent entity it is about to be folded into has commanded a €475 million valuation in a concurrent capital raise. That chasm helps explain why the junior stock has been among the most volatile names in the sector, touching a new 52-week high of €5.70 this week as the countdown to a major corporate restructuring accelerates.
Shares of Biogena Group Invest jumped 6.54% to that record level on Tuesday, bringing the weekly gain to 22.32% and the year-to-date advance to an impressive 93.15%. The move came as the subscription period for the parent company’s equity offering enters its final hours: the deadline to purchase new shares in Biogena Good Vibes AG expires this Wednesday, 22 July. The offering comprises five million new shares priced at €4.803 each, targeting gross proceeds of up to €25 million and implying the €475 million valuation for the holding company.
Founder Albert Schmidbauer, who controls more than 90% of the equity ahead of the emission, is expected to remain the majority shareholder after the transaction – a structure that underscores the group’s continued dependence on its creator even as it prepares for a public listing. The parent’s shares are slated to begin trading on the Vienna Stock Exchange’s direct market plus segment around 27 August, with the admission application due to be filed by 13 August.
Should investors sell immediately? Or is it worth buying Biogena Group Invest?
The group’s financials provide the foundation for that ambition. In the 2024/25 fiscal year, Biogena generated roughly €125 million in revenue, with EBIT of €8.54 million and EBITDA of €19.08 million. Net profit came in at €1.82 million. For the current year, management has set a revenue target of more than €150 million, and by 2030 the goal is to cross the €500 million threshold, driven primarily by online channels and the German pharmacy business. The company currently employs over 480 people across more than 70 countries.
A structural merger now appears inevitable. After the parent’s listing, management intends to pursue a consolidation of Biogena Good Vibes AG with its subsidiary, Biogena Group Invest, though the exact exchange ratio has yet to be determined. For existing shareholders of the junior stock, the next few weeks will be critical: the subscription deadline passes first, then all eyes turn to the IPO in late August and the subsequent integration talks that could reshuffle the group’s entire ownership base.
Ad
Biogena Group Invest Stock: New Analysis - 21 July
Fresh Biogena Group Invest information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
